Thiazolidinediones as anti-inflammatory and anti-atherogenic agents

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 1, 2008, Pages 14-26

  Ceriello, Antonio ^a  

^a WALSGRAVE HOSPITAL   (United Kingdom)

Author keywords

Anti atherogenic; Anti inflammatory; Free radicals; Oxidative stress; Pioglitazone; Rosiglitazone

Indexed keywords

ADIPONECTIN; BLOOD CLOTTING FACTOR; C REACTIVE PROTEIN; FIBRINOGEN; GELATINASE A; GELATINASE B; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLITAZONE DERIVATIVE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; METFORMIN PLUS ROSIGLITAZONE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXYNITRITE; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA; THROMBIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VOGLIBOSE; VON WILLEBRAND FACTOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLYCATION; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOREACTIVITY; INFLAMMATION; INSULIN RESISTANCE; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION; THROMBOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-INFLAMMATORY AGENTS; ATHEROSCLEROSIS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FREE RADICALS; HUMANS; HYPERLIPIDEMIAS; INFLAMMATION; OXIDATIVE STRESS; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLIDINEDIONES; TUNICA INTIMA;

EID: 38749105771     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.790     Document Type: Review

References (160)

1. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615-1625.
2. Calkin AC, Allen TJ. Diabetes mellitus-associated atherosclerosis: mechanisms involved and potential for pharmacological invention. Am J Cardiovasc Drugs 2006; 6: 15-40.
3. Schneider CA. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control. Curr Med Res Opin 2006; 22(Suppl. 2): S15-S26.
4. Ceriello A. Oxidative stress and diabetes-associated complications. Endocr Pract 2006; 12(Suppl. 1): 60-62.
5. Filippo CD, Cuzzocrea S, Rossi F, Marfella R, D'Amico M. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev 2006; 24: 77-87.
6. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459.
7. Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis. J Cardiovasc Risk 2001; 8: 187-194.
8. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-435.
9. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
10. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-206.
11. Ceriello A, Johns D, Widel M, Eckland D J, Gilmore K J, Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005; 28: 266-272.
12. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients. Diabetologia 2001; 44: 2210-2219.
13. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
14. Staels B. PPARγ and atherosclerosis. Curr Med Res Opin 2005; 21: S13-S20.
15. Pasceri V, Wu HD, Willerson JT, Yeh ET. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-238.
16. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46(Suppl. 1): M9-16.
17. de Groot H. Reactive oxygen species in tissue injury. Hepatogastroenterology 1994; 41: 328-332.
18. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004; 53(Suppl. 1): S110-S118.
19. Landmesser U, Harrison DG, Drexler H. Oxidant stress-a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 2006; 62(Suppl. 13): 13-19.
20. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest 1997; 100: 213-2157.
21. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111: 2518-2524.
22. Du X, Edelstein D, Obici S, Higham N, Zou MH, Brownlee M. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116: 1071-1080.
23. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24: 816-823.
24. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
25. Shiojiri T, Wada K, Nakajima A, et al. PPAR gamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 2002; 448: 231-238.
26. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002; 16: 1027-1040.
27. Sivarajah A, Chatterjee PK, Patel NS, et al. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/ reperfusion injury. Am J Nephrol 2003; 23: 267-276.
28. Mehta JL, Hu B, Chen J, Li D. Pioglitazone inhibits LOX 1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 2003; 23: 2203-2208.
29. Tsuji T, Mizushige K, Noma T, et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001; 38: 868-874.
30. Tsuji T, Mizushige K, Noma T, Murakami K, Miyatake A, Kohno M. Improvement of aortic wall distensibility and reduction of oxidative stress by pioglitazone in pre-diabetic stage of Otsuka Long-Evans Tokushima fatty rats. Cardiovasc Drugs Ther 2002; 16: 429-434.
31. Bagi Z, Koller A, Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol 2004; 286: H742-H748.
32. Iida KT, Kawakami Y, Suzuki M, et al. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 2003; 284: E1125-E1130.
33. Makino H, Miyamoto Y, Sawai K, et al. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 2006; 55: 2747-2756.
34. Mori Y, Itoh Y, Obata T, Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 2006; 29: 143-148.
35. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867-875.
36. Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 2006; 29: 1039-1045.
37. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499.
38. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005; 46: 773-778.
39. Pfutzner A, Marx N, Lubben G, et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931.
40. Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24: 2047-2055.
41. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-2104.
42. Combs TP, Wagner JA, Berger J, et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 2002; 143: 998-1007.
43. Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005; 69: 5-13.
44. Dong FQ, Li H, Cai WM, et al. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J (Engl) 2004; 117: 1040-1044.
45. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
46. Esposito K, Ciotola M, Carleo D, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29: 1071-1076.
47. Forst T, Hohberg C, Fuellert SD, et al. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 2005; 37: 521-527.
48. Game BA, He L, Jarido V, et al. Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis 2007; 192: 85-91.
49. Ghanim H, Dhindsa S, Aljada A, Chaudhuri A, Viswanathan P, Dandona P. Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 2006; 91: 3553-3558.
50. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554.
51. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
52. Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. J Intern Med 2007; 261: 293-305.
53. Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25: 1804-1809.
54. Hetzel M, Walcher D, Grub M, Bach H, Hombach V, Marx N. Inhibition of MMP-9 expression by PPARgamma activators in human bronchial epithelial cells. Thorax 2003; 58: 778-783.
55. Kato K, Satoh H, Endo Y, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 1999; 258: 431-435.
56. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
57. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomised study. Circulation 2005; 111: 2525-2531.
58. Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005; 65: 907-912.
59. Majuri A, Santaniemi M, Rautio K, et al. Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study. Eur J Endocrinol 2007; 156: 263-269.
60. Marfella R, D'Amico M, Esposito K, et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 2006; 55: 622-632.
61. Marx N, Walcher D, Ivanova N, et al. Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products. Diabetes 2004; 53: 2662-2668.
62. Otto C, Otto B, Goke B, et al. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest 2006; 29: 231-236.
63. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N, Nadler JL. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta 2000; 301: 65-77.
64. Shimizu H, Oh-I S, Tsuchiya T, Ohtani KI, Okada S, Mori M. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabet Med 2006; 23: 253-257.
65. Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004; 147: e25.
66. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-934.
67. Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182-188.
68. Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006; 98: 1057-1062.
69. Zirlik A, Leugers A, Lohrmann J, et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004; 91: 674-682.
70. Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab 1999; 25(Suppl. 3): 32-40.
71. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production. Diabetes 2000; 49: 1231-1238.
72. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 2005; 31: 429-439.
73. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772.
74. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-1437.
75. Touboul P-J, Elbaz A, Koller C, et al. Common carotid artery intima media thickness and brain infarction. Circulation 2000; 102: 313-318.
76. Wagenknecht LE, D'Agostino R Jr, Savage PJ, O'Leary DH, Saad MF, Haffner SM. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 999-1005.
77. Bonora E, Kiechl S, Oberhollenzer F, et al. Impaired glucose tolerance, Type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia 2000; 43: 156-164.
78. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792-2798.
79. Trial identifier NCT00225264. Available at: www.ClinicalTrials.gov. Accessed October 13, 2006.
80. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581.
81. Trial identifier NCT00225277. Available at: www.ClinicalTrials.gov. Accessed October 13, 2006.
82. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
83. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension 1988; 12: 530-548.
84. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
85. Colwell JA. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs 2004; 4: 87-106.
86. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24: 1476-1485.
87. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am 1990; 4: 1-26.
88. Akai T, Naka K, Okuda K, Takemura T, Fujii S. Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metab Res 1983; 15: 523-526.
89. Nolan RD, Platt KH, Loose PG. The resistance to nitric oxide inhibition of platelet aggregation is due to decreased phosphorylation of rap 1B in platelets of NIDDM compared with control subjects. Diabetes 1994; 43(Suppl. 1): 101A.
90. Hishinuma T, Yamazaki T, Mizugaki M. Troglitazone has a reducing effect on thromboxane production. Prostaglandins Other Lipid Mediat 2000; 62: 135-143.
91. Ishizuka T, Itaya S, Wada H, et al. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Diabetes 1998; 47: 1494-1500.
92. Ray DM, Spinelli SL, O'Brien JJ, Blumberg N, Phipps RP. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease. BioDrugs 2006; 20: 231-241.
93. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109(Suppl. 1): IV6-I19.
94. Juhan-Vague I, Vague P, Alessi MC, et al. Relationships between Plasma insulin triglyceride, body mass index, and plasminogen activator inhibitor 1. Diabete Metab 1987; 13: 331-336.
95. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-1364.
96. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003; 108: 420-425.
97. Aso Y, Wakabayashi S, Yamamoto R, Matsutomo R, Takebayashi K, Inukai T. Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor 1 and thrombin-activatable fibrinolysis inhibitor. Diabetes Care 2005; 28: 2211-2216.
98. Mavri A, Alessi MC, Juhan-Vague I. Hypofibrinolysis in the insulin resistance syndrome: implication in cardiovascular diseases. J Intern Med 2004; 255: 448-456.
99. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A 1992; 89: 6998-7002.
100. Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 2006; 186: 240-259.
101. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91: 3527-3561.
102. Dunn EJ, Ariens RA. Fibrinogen and fibrin clot structure in diabetes. Herz 2004; 29: 470-479.
103. Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin structure and function. Diabetologia 2005; 48: 1198-1206.
104. Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994; 91: 7742-7746.
105. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14: 1521-1528.
106. Dandona P, Aljada A, Chaudhuri A, Mohanty P. Endothelial dysfunction, inflammation and diabetes. Rev Endocr Metab Disord 2004; 5: 189-197.
107. Warner SJ, Libby P. Human vascular smooth musde cells. Target for and source of tumor necrosis factor. J Immunol 1989; 142: 100-109.
108. Tipping PG, Hancock WW. Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol 1993; 142: 1721-1728.
109. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297-302.
110. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-241.
111. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-2312.
112. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet 1990; 335: 294-295.
113. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-2153.
114. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab 1998; 83: 2907-2910.
115. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995; 95: 2111-2119.
116. Picchi A, Gao X, Belmadani S, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 2006; 99: 69-77.
117. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 2002; 8: RAS-R12.
118. Baumann H, Gauldie J. The acure phase response. Immunol Today 1994; 15: 74-80.
119. Trujillo ME, Scherer PE. Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175.
120. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-2568.
121. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
122. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity, Biochem Biophys Res Commun 1999; 257: 79-83.
123. Haque WA, Shimomura I, Matsuzawa Y, Garg A. Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002; 87: 2395.
124. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-1785.
125. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
126. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-58.
127. Spranger J, Kroke A, Mohlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
128. Pepys MB. C-reactive protein fifty years on. Lancet 1981; 1: 653-657.
129. Castell JV, Andus T, Kunz D, Heinrich PC. Interleukin-6. The major regulator of acute-phase protein synthesis in man and rat. Ann N Y Acad Sci 1989; 557: 87-99.
130. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
131. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.
132. Lagrand WK, Niessen HW, Wolbink GJ, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997; 95: 97-103.
133. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
134. Lotz M. Interleukin-6. Cancer Invest 1993; 11: 732-742.
135. Kanda T, Takahashi T. Interleudin-6 and cardiovascular diseases. Jpn Heart J 2004; 45: 183-193.
136. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 1989; 8: 3773-3779.
137. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263-271.
138. Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512.
139. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
140. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
141. Esposito K, Nappo F, Giugliano F, et al. Cytokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care 2003; 26: 1647.
142. Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and intefleukin-6 mRNA expression in a murine model of noninsulin-dependent diabetes. Biochem Pharmacol 2000; 60: 67-75.
143. Lee SW, Song KE, Shin DS, et al. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. Diabetes Res Clin Pract 2005; 69:175-179.
144. Death AK, Fisher EJ, McGrath KC, Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003; 168: 263-269.
145. Loftus IM, Naylor AR, Bell PR, Thompson MM. Plasma MMP-9 - a marker of carotid plaque instability. Eur J Vasc Endovasc Surg 2001; 21: 17-21.
146. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: 380-384.
147. Cu H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-372.
148. Erdmann E, Dormandy JA, Charbonnel B, Messy-Benedetti M, Meals IK, Skene AM. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780.
149. Wilcox R, Bousser MG, Betteridge J, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873.
150. Trial identifier NCT00094796. Available at: www.ClinicalTrials.gov. Accessed February 25, 2006.
151. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. http://content.nejm.org/cgi/reprint/ NEJMoa072761.pdf?resourcetype=HWCIT.
152. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356: 2522-2524. http://content.nejm.org/cgi/ reprint/NEJMe078099.pdf?resourcetype=HWCIT.
153. The Rosiglitazone Story - Lessons from an FDA Advisory Committee Meeting. Available at: N Engl J Med 2007. http://content.nejm.org/cgi/ content/full/NEJMp078167.
154. Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105.
155. Kahn SE, Haffner SM, Hiss MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
156. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Sough 2007; 16: 1065-1071.
157. EMEA statement on recent publication on cardiac safety of rosiglitazone (Avandia, Avandamet, Avaglim). Available at: http://www.emea.europa.aye/ pdfs/general/direct/pr/2300-ann.pdf. Accessed May 23, 2007.
158. The Lancet Editorial. Rosiglitazone: seeking a balanced perspective. Lancet 2007; 369: 1834.
159. ACCORD. Available at: http://www.accordtrial.org/public/index.cfm. Accessed May 11, 2006.
160. Bypass angioplasty revascularization investigation in type 2 diabetes (BIER 2D). Available at: http://www.clinicaltrials.gov/ct/show/ NCT00006305?order=l. Accessed April 27, 2007.